Protara Therapeutics, Inc. (TARA)

Protara Therapeutics' stock price has experienced volatility in the past six months. In February 2026, the stock fell approximately 22% following the release of updated interim data from its Phase 2 ADVANCED-2 trial. In March 2026, the company announced confirmation of a 68.0% six-month complete response rate for TARA-002 in BCG-unresponsive NMIBC patients. Earlier, in early 2025, the company completed a significant public offering that provided funding for its clinical development programs.

There is no explicit information available regarding demand seasonality for Protara Therapeutics, Inc.'s products or services. Demand for its products is typically driven by disease prevalence, clinical trial outcomes, regulatory approvals, and treatment efficacy rather than seasonal patterns.

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Their primary product pipeline includes TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride for patients receiving parenteral support. TARA-002 has received FDA Breakthrough Therapy and Fast Track designations for pediatric patients with LMs.

Protara Therapeutics, Inc. is headquartered in New York, NY, United States. The company conducts early-stage clinical trials in North America. Its common stock is traded on the Nasdaq Global Market under the ticker symbol TARA. Furthermore, Protara Therapeutics Inc. is listed on several European stock exchanges, including Stuttgart, Frankfurt, Munich, Dusseldorf, and Hamburg.

Protara Therapeutics has maintained a generally positive brand reputation, particularly among analysts, who have given it a consensus rating of "Moderate Buy." Positive events impacting its reputation include encouraging interim results from its Phase 2 ADVANCED-2 trial for TARA-002 in bladder cancer, and the FDA's granting of Breakthrough Therapy and Fast Track designations for TARA-002 in pediatric lymphatic malformations. However, the stock's approximately 22% decline in February 2026 could have temporarily impacted its market perception.

Protara Therapeutics, Inc.'s ownership is significantly weighted towards institutional investors. As of March 31, 2026, the company had 108 institutional owners and shareholders holding a total of 38,979,495 shares. Major institutional owners include Janus Henderson Group Plc, Velan Capital Investment Management LP, BlackRock, Inc., Vanguard Group Inc, Blackstone Group Inc, Acorn Capital Advisors, Llc, Sio Capital Management, LLC, Catalio Capital Management, LP, Integral Health Asset Management, LLC, and 5AM Venture Management, LLC. Individual insider owners include Hubert Birner, who holds 10.41% of the company's shares.